Status Awaiting development
Technology type Medicine
Decision None selected
Process STA
ID number 4014

Provisional Schedule

Committee meeting: 1 10 November 2022
Expected publication 01 February 2023

Project Team

Project lead Jeremy Powell

Email enquiries

External Assessment Group Bristol Technology Assessment Group, University of Bristol


Companies sponsors Janssen
Others Department of Health and Social Care
  NHS England
  NHS Kingston CCG
  NHS Lancashire North CCG
  Welsh Government
Patient carer groups Black Health Agency for Equality
  Blood Cancer UK
  Cancer Black Care
  Cancer Equality
  Cancer 52
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Leukaemia Cancer Society
  Leukaemia CARE
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Myeloma UK
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Association of Cancer Physicians
  British Committee for Standards in Haematology
  British Blood Transfusion Society
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Society for Haematology
  Cancer Research UK
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Myeloma Forum
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society
Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare (bortezomib, lenalidomide, thalidomide)
  Advanz pharma (dexamethasone)
  Aspen (dexamethasone)
  Aspire (bortezomib, dexamethasone)
  Bristol-Myers Squibb (lenalidomide)
  Celgene (thalidomide)
  Consilient health (dexamethasone)
  Focus Pharmaceuticals (dexamethasone)
  Hameln Pharmaceuticals
  Hospira (dexamethasone)
  Janssen (bortezomib)
  Martindale pharma (dexamethasone)
  Merck, Sharp and Dohme (dexamethasone)
  Mylan (bortezomib)
  Piramal Critical Care (lenalidomide)
  Rosemont Pharmaceuticals (dexamethasone)
  Sandoz (bortezomib)
  Teva (dexamethasone)
  Thornton & Ross (bortezomib)
  Zentiva (bortezomib)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Bone Cancer Research Trust
  Cochrane Haematological Malignancies Group
  Geonomics England
  Institute of Cancer Research
  Leukaemia UK
  Leukaemia Busters
  MRC Clinical Trials Unit
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
25 March 2022 Invitation to participate
17 February 2022 - 10 March 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
26 November 2021 Following a request received from the company, NICE will be undertaking an appraisal of Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma. This was originally terminated guidance TA634. The appraisal is expected to start during January 2022 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the appraisal during mid-March 2022. The deadline for submissions is expected in approximately late May 2022.

For further information on our processes and methods, please see our CHTE processes and methods manual